ALXN - Plenty More Upside To See In Alexion Pharmaceuticals In 2020

• The market has shown strong support for Alexion YTD, where shareholders have enjoyed +64.28% since the selloff in March.
• Strong revenue growth on healthy margins paints the picture for periods to come, with equally as satisfying FCF positioning and capital structure.
• New level of support has been realised recently, with the stock bouncing off the new support line twice to today's trading.
• Upgrade to relative strength supports this bullish outlook, and investors may benefit from 5-15% upside in a dislocation in valuation to price.
• We are bullish on Alexion setting a price target of $142 and are eager to provide full coverage after their third quarter earnings release.

For further details see: